| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2017: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2016: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
Heart is a main target for regenerative medicine. In this study, we aimed at discovering a novel progenitor cell population which can specifically differentiate into cardiomyocytes even under non-specific environments including heart tissue after cell transplantation. We found that CD82-positive cells during human iPS cell differentiation highly effciently (>95%) gave rise to cardiomyocytes after transplantation to mouse/rat animal models (Takeda, Cell Reports, 2018). Currently, we are examining functional improvement of infarct hearts after the cell transplantation. This cell population would be a novel cell source for cardiac regeneration therapy.
|
